UCE1022，一种来自拟青霉的具有拓扑异构酶I介导的DNA切割活性的新型抗肿瘤抗生素。 - Suppr | 超能文献

UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces.

作者信息

Fujii N, Yamashita Y, Ando K, Agatsuma T, Saitoh Y, Gomi K, Nishiie Y, Nakano H

出版信息

J Antibiot (Tokyo). 1994 Aug;47(8):949-51. doi: 10.7164/antibiotics.47.949.

DOI:10.7164/antibiotics.47.949

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

UCE1022, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from Paecilomyces.UCE1022，一种来自拟青霉的具有拓扑异构酶I介导的DNA切割活性的新型抗肿瘤抗生素。

J Antibiot (Tokyo). 1994 Aug;47(8):949-51. doi: 10.7164/antibiotics.47.949.

2

Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces.圣托品，一种来自拟青霉的具有拓扑异构酶II依赖性DNA切割活性的新型抗肿瘤抗生素。

J Antibiot (Tokyo). 1990 Oct;43(10):1344-6. doi: 10.7164/antibiotics.43.1344.

3

Novel selective inhibitors for human topoisomerase I, BM2419-1 and -2 derived from saintopin.新型人拓扑异构酶I选择性抑制剂，源自喜树碱的BM2419 - 1和-2 。

J Antibiot (Tokyo). 1998 Dec;51(12):1069-74. doi: 10.7164/antibiotics.51.1069.

4

UCE6, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes.UCE6是一种来自放线菌的新型抗肿瘤抗生素，具有拓扑异构酶I介导的DNA切割活性。

J Antibiot (Tokyo). 1993 Jul;46(7):1173-4. doi: 10.7164/antibiotics.46.1173.

5

UCE6, a new antitumor antibiotic with topoisomerase I-mediated DNA cleavage activity produced by actinomycetes: producing organism, fermentation, isolation and biological activity.UCE6，一种由放线菌产生的具有拓扑异构酶I介导的DNA切割活性的新型抗肿瘤抗生素：产生菌、发酵、分离及生物活性

J Antibiot (Tokyo). 1997 Jun;50(6):490-5. doi: 10.7164/antibiotics.50.490.

6

Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.新型真菌抗肿瘤剂圣托品诱导哺乳动物DNA拓扑异构酶I和II介导的DNA裂解

Biochemistry. 1991 Jun 18;30(24):5838-45. doi: 10.1021/bi00238a005.

7

Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics.喜树碱类抗生素与拓扑异构酶I形成可裂解复合物的能力与其生长抑制活性之间的相关性。

Mol Pharmacol. 1997 Feb;51(2):269-76. doi: 10.1124/mol.51.2.269.

8

The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.喜树碱耐药的拓扑异构酶I突变体F361S对抗肿瘤瑞贝卡霉素衍生物具有交叉耐药性。吲哚咔唑抑制拓扑异构酶I的模型。

Biochemistry. 1999 Jul 6;38(27):8605-11. doi: 10.1021/bi983052y.

9

Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts.抗肿瘤药物VM 26、福司曲星和喜树碱导致的拓扑异构酶中毒对哺乳动物细胞提取物DNA修复复制的影响。

Carcinogenesis. 1992 Aug;13(8):1371-7. doi: 10.1093/carcin/13.8.1371.

10

Isolation of 3 alpha-hydroxy-3,5-dihydro ML-236C (sodium salt) from paecilomyces viridis L-68.

J Antibiot (Tokyo). 1994 Jan;47(1):108-9. doi: 10.7164/antibiotics.47.108.

引用本文的文献

1

Secondary Metabolites and Their Bioactivities Produced by .海洋真菌. 产生的次生代谢产物及其生物活性

Molecules. 2020 Nov 1;25(21):5077. doi: 10.3390/molecules25215077.